Achieve Life Sciences, Inc.

Business Description

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Key Statistics
Market Cap: 107308080.0
ROIC: -93.57% (7 yrs)
Net Income Yield: -39.02%
Current PE: -2.84
Corporate Information
Exchange: NASDAQ Capital Market
Address: 1040 West Georgia Street
CEO: Mr. John A. Bencich M.B.A.
Current Stock Price: 4.345